You waited six weeks for the blood draw to become a report. The report arrived, and it says no clinically significant findings. Somewhere between the waiting and the reading, you had built an expectation that a name was coming. A gene, a syndrome, a support group full of families whose kids share the same variant. Instead the letter is one page long and says, in careful clinical language, that the lab found nothing to tell you.

That page is one of the most misread documents in pediatric genetics. It does not say your child has no genetic cause. It says that the specific test that was ordered, read against the reference databases as they existed on the day it was interpreted, did not turn up a variant the lab was willing to call. Those are different statements, and the distance between them is where families lose months.

The Numbers Behind a Negative Report

Autism is not a condition that a genetic test diagnoses. More than 100 genes have documented ties to autism, and none of them functions as a test you pass or fail. Across everyone with an autism diagnosis, a specific genetic cause is identified in fewer than 25% of cases.

The yield depends heavily on which test was run. Chromosomal microarray, which looks for missing or duplicated chunks of chromosome, identifies a cause in roughly 10% of autistic children. Whole genome sequencing, which reads the sequence itself, has identified relevant variants in about 34% of cases in published research. If your child had a microarray and nothing else, the report you are holding reflects a test that was never designed to see most of what it might have found.

Genetics is a map with blank regions, and geneticists are honest about where those regions sit. Our reference databases were built from the people who have been sequenced so far, and that population skews toward European ancestry and toward children with severe, early, obvious presentations. A variant that is genuinely causing your child's differences can sit in the report as unremarkable because no one has yet published a case linking it to anything.

The Result That Is Neither Yes Nor No

Some families receive a third category and mistake it for a negative. A variant of uncertain significance, usually written as VUS, means the lab found a change in a gene and cannot say whether it matters. A VUS is not a diagnosis, and it is not an empty result either.

A VUS is the finding most likely to change. As more people are sequenced and more cases are published, the lab reclassifies. Variants move to pathogenic, and variants move to benign. If your report contains a VUS, write down the gene name and the exact variant notation before the paperwork gets filed. You will want it when you ask for reanalysis.

Your Report Has a Shelf Life

Genetic reports are interpretations, and interpretations expire. Almost no family is told this at the appointment. The raw sequencing data your child produced does not change. What changes is the body of published knowledge the lab compares it against, and that body grows every month. Studies that reanalyzed previously negative exome data have produced new diagnoses in roughly 5% to 15% of those cases, with the yield rising the longer the gap between the original report and the reanalysis.

You can request that reanalysis. Ask your geneticist or genetic counselor to submit the existing data for reinterpretation, and ask them how long the lab retains raw data, because policies vary and some labs do not keep it indefinitely. A reasonable rhythm is to ask every 18 to 24 months, and to ask sooner if a new feature emerges in your child, such as seizures or a regression or a heart finding, because a new clinical detail gives the lab a new search to run. A negative result from 2021 is not a negative result in 2026; it is a snapshot of what was knowable in 2021.

Ask Whether the Right Test Was Ordered

Before you accept the result as final, find out which test was run. The current American Academy of Pediatrics guidance recommends chromosomal microarray as a first-tier evaluation for global developmental delay and intellectual disability, with exome sequencing alongside it rather than years later.

Three questions get you most of the way:

• Which test was performed, by name, and was it microarray, exome, or genome sequencing?
• Was Fragile X testing done separately, since microarray does not detect it?
• Was this a solo test on my child, or a trio that also sequenced both parents?

Trio testing matters more than most families are told. Sequencing the parents alongside the child lets the lab see which variants are new in your child rather than inherited, and new variants are far more likely to be the ones causing a difference. A solo test throws away that signal. If your child had a solo test, a trio reanalysis of the same data plus two parental samples is often the highest-yield next step available.

If sequencing has not been done at all, whole genome sequencing is the conversation to have.

What the Negative Does Not Touch

Your child's eligibility for early intervention, for an IEP, for speech therapy, for occupational therapy, for insurance coverage of applied behavioral services: none of it runs through a genetics report. Eligibility is determined by the clinical diagnosis and by demonstrated need, and no school district asks for a gene.

Nor does the absence of a finding mean the cause is behavioral, environmental, or something you did. Autism is among the most heritable of the neurodevelopmental conditions, and heritability is measured in twin and family studies, not in whether one lab could name one gene in one child on one Tuesday.

Where a negative result does have consequences is recurrence risk. Without an identified variant, no one can give you a precise number for a future pregnancy, and the counseling shifts to population and family-history estimates. That conversation belongs with a genetic counselor, who can also tell you whether direct-to-consumer results or a polygenic risk score have any bearing on your family, which in nearly every case they do not.

The Next Appointment

Bring the report. Bring the exact test name off the first page. Ask what the lab's data retention policy is, ask whether a trio reanalysis is possible with the samples on hand, and put a date 18 months out in your calendar labeled with the word reanalysis and the name of the lab.

The blank page you are holding is the current edge of what genetics can see, and edges move. Yours will be somewhere different in two years, and the families who get the eventual answer are usually the ones who kept asking the lab to look again.